Recombinant human IFN-α2b protein - Bioactive cytokine

Recombinant cytokine, source: CHO cells

ABOUT

Human IFN-α2b protein - Mammalian cell-expressed, tag-free, with HSA

Recombinant human IFN-α2b is a high-quality and biologically active cytokine, validated using proprietary IFN-α/β reporter cells. This IFN-α subtype from the type I interferons family is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure.

Recombinant human IFN-α2b can be used together with HEK-Blue™ IFN-α/β cells for the screening of inhibitory molecules, such as Rontalizumab and Aniftrolumab, two monoclonal antibodies targeting IFN-α and its receptor, respectively (see figures).

 

Key features

  • Each lot is validated using HEK-Blue™ IFN-α/β cells
  • Endotoxin < 1 EU/µg
  • 0.2 µm sterile-filtered

Applications

  • IFN-α2b detection and quantification assays (positive control)
  • Screening and release assays for antibodies blocking IFN-α2b signaling
  • Screening and release assays for engineered IFN-α2b proteins

 

Interferon alpha 2b (IFN-α2b) is the prototypic subtype of IFN-α used in fundamental research and most clinical applications. Despite its anti-viral protective effects, excessive IFN-α contributes to the pathogenesis of immune-mediated inflammatory diseases, including systemic lupus erythematosus (SLE) and STING-associated vasculopathy with onset in infancy (SAVI).

more detailsMore details

All InvivoGen products are for internal research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Source
CHO cells
Species
Human
Synonyms
IFN-alpha 2
Accession sequence

P01563

Protein size
165 a.a. (C24-E188)
Molecular weight
~17-20 kDa (SDS-PAGE)
International units (IU)

Please refer to the corresponding Certificate of Analysis (CoA)

Carrier
HSA
Tag
Tag-free
Purity
≥ 95% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

Phosphate buffer saline (pH 7.4), 5% saccharose, 2% HSA

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Sterility

0.2 µm filtration

Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Applications

Cellular assays (tested), ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Recombinant human IFN-α2b
  • Cat code: 
    rcyc-hifna2b-1
  • Quantity: 
    10 µg
Includes:

1.5 ml endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C
    Stability: -20°C for up to 6 months

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

The human interferon-alpha family

IFN-α signaling

Type I interferons (IFN) include the IFN-α family, IFN-β, IFN-ε, IFN-κ, and IFN-ω. IFN-αs are important anti-viral cytokines that also have anti-proliferative and immuno-modulatory functions. The human IFN-α family comprises 13 genes encoding 12 proteins, with IFN-α13 being identical to IFN-α1. All IFN-αs bind to a common heterodimer receptor IFNAR1/IFNAR2. The ternary complex signals through the Janus kinase (JAK) and signal transducer and activator of the transcription (STAT) signaling pathway, inducing the formation of the ISGF3 transcriptional complex (STAT1/STAT2/IRF9). ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoter regions of numerous IFN-stimulated genes (ISGs) [1].

Human IFN-α genes have evolved under strong selective pressure, suggesting a non-redundant role between IFN-α subtypes [2]. Although most studies have focused on IFN-α2 and IFN-α8, a consensus model for all IFN-αs has emerged depending on the affinity of a particular IFN-α subtype for IFNAR. Low-affinity IFN-α subtypes signal strictly through ISGF3 and induce robust ISGs, such as PKR, ISG56, and IFI16, which display anti-viral functions. Conversely, high-affinity IFN-α subtypes signal through ISGF3 and other factors, which activate “tunable” ISGs” such as CXCL10, IL-8, and ISG15, that induce anti-proliferative and immuno-modulatory functions [3]. IFN-α8, IFN-α10, and IFN-α14 have been identified as the most potent inducers of ISGs, while IFN-α1 is the weakest [4].

 

Human interferon-alpha 2b

The human interferon α2 (hIFN-α2) was the first highly active IFN subtype to be cloned and available for research. For this reason, hIFN-α2 has been the prototypic IFN-α among all other subtypes of this family used in fundamental research and most clinical applications [5, 6]. Human IFN-α2a and-α2b are allelic variants differing by a neutral lysine to arginine substitution at position 23 of the mature protein, respectively [5,6]. They are the only IFN-α subtypes with an O-glycosylation site (on Thr106) [6].

 

Human interferon-alpha 10

Natural human IFN-α10 is induced in peripheral blood mononuclear cells upon incubation with CpG-oligonucleotides and in plasmacytoid dendritic cells upon incubation with CpG-oligonucleotides or imiquimod [7]. This subtype of IFN-α is classified among the top three strongest ISG inducers [4, 8] with high anti-viral activity in vitro against human metapneumovirus [9] and hepatitis C virus (HCV) [10]. Human IFN-α10 displays a strong capacity to induce IFIT1, CXCL10, CXCL11, ISG15, and CCL8 [8]. Human IFN-α10 expression is IFN-α receptor-dependent as it is induced by other IFN-α subtypes upon infection with low doses of Sendai virus in vitro [11].

 

IFN-α subtypes available upon request for a minimum quantity : Please contact us

SubtypeAlternate nameUnitProd IDSource
IFN-α1IFN-alpha DP01562CHO
IFN-α4aIFN-alpha M1P05014CHO
IFN-α5IFN-alpha GP01569CHO
IFN-α6IFN-alpha KP05013CHO
IFN-α7IFN-alpha J1P01567CHO
IFN-α8IFN-alpha B2P31881CHO
IFN-α14IFN-alpha H2P01570HEK293
IFN-α16IFN-alpha WAP05015CHO
IFN-α17IFN-alpha IP01571CHO
IFN-α21IFN-alpha FP01568CHO

References 

1. Schreiber G. 2017. The molecular basis for differential type I interferon signaling. J. Biol. Chem. 292:7285-94.
2. Manry J. et al., 2011. Evolutionary genetic dissection of human interferons. J. Exp. Med. 208:2747-59.
3. Levin D. et al., 2014. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal. 7(327). ra50.
4. Kurunganti S. et al., 2014. Production and characterization of thirteen human type-I interferon-α subtypes. Protein Expr. Purif. 103: 75-83.
5. Paul F. et al., 2015. IFNA2: The prototypic human interferon. Gene.
6. Antonelli G. et al., 2015. Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 26(2):121-31.
7. Hillyer P. et al., 2012. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol. Cell. Biol. 90(8):774.
8. Moll H.P. et al., 2011. The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types. Cytokines. 53:52.
9. Scagnolari C. et al., 2011. In vitro sensitivity of human metapneumovirus to type I interferons. Viral Immunol. 24(2):159.
10. Koyama T. et al., 2006. Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol. Res. 34(1):41.
11. Zaritsky L.A. et al., 2015. Virus multiplicity of infection affects type I interferon subtype induction profiles and interferon-stimulated genes. J. Virol. 89:11534.
 

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?